|
 | | | |
 |
 |
 |
||||||||
|
||||||||
 |
||||||||
| olivia thomas | 29 มี.ค. 2568 11:32 IP Address: |
 ผู้ดูแลเว็บไซต์ |
Gefitinibis a Breakthrough in Targeted Cancer Therapy
Gefitinib is a tyrosine kinase inhibitor (TKI) primarily used for the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. It works by blocking the EGFR pathway, preventing cancer cell growth and proliferation. Due to its targeted action, Gefitinib offers higher efficacy with fewer side effects compared to traditional chemotherapy. Patients diagnosed with EGFR-mutant NSCLC benefit from Gefitinib as a first-line therapy, significantly improving progression-free survival. The drug is available in oral tablet form, making it convenient for long-term treatment. However, proper medical supervision is necessary to manage potential side effects like diarrhea, rash, and liver function abnormalities. A reliable Manufacturer of Gefitinib ensures high-quality production adhering to international regulatory standards, making the drug accessible and affordable for patients worldwide. As research continues, Gefitinib remains a cornerstone in precision oncology, offering hope for improved cancer treatment outcomes. Tidarat |
Copyright 2015 (C) yiipoon.com All rights
